Document is current
Any future updates will be listed below
-
Authors
Cong, Ying
Biemans, Rianne
Lieuwes, Natasja G.
Suijlen, Dennis
Lambin, Philippe
Dijkgraaf, Ingrid
Bauwens, Matthias
Yaromina, Ala
Dubois, Ludwig J. https://orcid.org/0000-0002-8887-4137
-
Funding
Funding for this research was provided by:
China Scholarship (202006100044)
ERC Advanced - Hypoximmuno (ERC-ADG-2015 n° 694812)
- License Information
-
More Information
Article History
Received: 21 January 2025
Accepted: 25 April 2025
First Online: 13 May 2025
Declarations
:
: The animal experiments were reviewed and approved by the animal welfare and ethics committees of Maastricht University.
: LJD has, outside of the submitted work, shares in Convert Pharmaceuticals and LivingMed Biotech, and he is co-inventor of a granted patent on LSRT (PCT/P126537PC00). PL has, outside of the submitted work, shares in Radiomics, Convert pharmaceuticals, Comunicare, LivingMed Biotech and Bactam, and he is co-inventor of issued patents on radiomics (PCT/NL2014/050248 and PCT/NL2014/050728), mtDNA (PCT/EP2014/059089), Radiomic signature of hypoxia (U.S. Patent 11,972,867), Prodrugs (WO2019EP64112), Deep Learning-Radiomics (N2024889) and one granted patent on LSRT (PCT/P126537PC00). The other authors have no relevant financial or non-financial interests to disclose.
